alexa Atrial fibrillation after cardiac surgery: a major morbid event?


Journal of Clinical & Experimental Cardiology

Author(s): Almassi GH, Schowalter T, Nicolosi AC, Aggarwal A, Moritz TE,

Abstract Share this page

Abstract OBJECTIVE: The purpose of the study was to investigate the incidence, predictors, morbidity, and mortality associated with postoperative atrial fibrillation (AF) and its impact on intensive care unit (ICU) and postoperative hospital stay in patients undergoing cardiac surgery in the Department of Veterans Affairs (VA). SUMMARY BACKGROUND DATA: Postoperative AF after open cardiac surgery is rather common. The etiology of this arrhythmia and factors responsible for its genesis are unclear, and its impact on postoperative surgical outcomes remains controversial. The purpose of this special substudy was to elucidate the incidence of postoperative AF and the factors associated with its development, as well as the impact of AF on surgical outcome. METHODS: The study population consisted of 3855 patients who underwent open cardiac surgery between September 1993 and December 1996 at 14 VA Medical Centers. Three hundred twenty-nine additional patients were excluded because of lack of complete data or presence of AF before surgery, and 3794 (98.4\%) were male with a mean age of 63.7+/-9.6 years. Operations included coronary artery bypass grafting (CABG) (3126, 81\%), CABG + AVR (aortic valve replacement) (228, 5.9\%), CABG + MVR (mitral valve replacement) (35, 0.9\%), AVR (231, 6\%), MVR (41, 1.06\%), CABG + others (95, 2.46\%), and others (99, 2.5\%). The incidence of postoperative AF was 29.6\%. Multivariate logistic regression analysis of factors found significant on univariate analysis showed the following predictors of postoperative AF: preoperative patient risk predictors: advancing age (odds ratio [OR] 1.61, 95\% confidence interval [CI] 1.48-1.75, p < 0.001), chronic obstructive pulmonary disease (OR 1.37, 95\% CI 1.12-1.66, p < 0.001), use of digoxin within 2 weeks before surgery (OR 1.37, 95\% CI 1.10-1.70, p < 0.003), low resting pulse rate <80 (OR 1.26, 95\% CI 1.06-1.51, p < 0.009), high resting systolic blood pressure >120 (OR 1.19, 95\% CI 1.02-1.40, p < 0.026), intraoperative process of care predictors: cardiac venting via right superior pulmonary vein (OR 1.42, 95\% CI 1.21-1.67, p < 0.0001), mitral valve repair (OR 2.86, 95\% CI 1.72-4.73, p < 0.0001) and replacement (OR 2.33, 95\% CI 1.55-3.55, p < 0.0001), no use of topical ice slush (OR 1.29, 95\% CI 1.10-1.49, p < 0.0009), and use of inotropic agents for greater than 30 minutes after termination of cardiopulmonary bypass (OR 1.36, 95\% CI 1.16-1.59, p < 0.0001). Postoperative median ICU stay (3.6 days AF vs. 2 days no AF, p < 0.001) and hospital stay (10 days AF vs. 7 days no AF, p < 0.001) were higher in AF. Morbid events, hospital mortality, and 6-month mortality were significantly higher in AF (p < 0.001): ICU readmission 13\% AF vs. 3.9\% no AF, perioperative myocardial infarction 7.41 \% AF vs. 3.36\% no AF, persistent congestive heart failure 4.57\% AF vs. 1.4\% no AF, reintubation 10.59\% AF vs. 2.47\% no AF, stroke 5.26\% AF vs. 2.44\% no AF, hospital mortality 5.95\% AF vs. 2.95\% no AF, 6-month mortality 9.36\% AF vs. 4.17\% no AF. CONCLUSIONS: Atrial fibrillation after cardiac surgery occurs in approximately one third of patients and is associated with an increase in adverse events in all measurable outcomes of care and increases the use of hospital resources and, therefore, the cost of care. Strategies to reduce the incidence of AF after cardiac surgery should favorably affect surgical outcomes and reduce utilization of resources and thus lower cost of care.
This article was published in Ann Surg and referenced in Journal of Clinical & Experimental Cardiology

Relevant Expert PPTs

Relevant Speaker PPTs

  • Donald silverberg
    Is correction of iron deficiency a new addition to the treatment of heart failure?
    PPT Version | PDF Version
  • Ahmed Zeidan
    Effects of intravenous iron in chronic kidney disease and heart failure
    PPT Version | PDF Version
  • Yosef Yarden
    Classically, the 3’untranslated region (3’UTR) is that region in eukaryotic protein-coding genes from the translation termination codon to the polyA signal. It is transcribed as an integral part of the mRNA encoded by the gene. However, there exists another kind of RNA, which consists of the 3’UTR alone, without all other elements in mRNA such as 5’UTR and coding region. The importance of independent 3’UTR RNA (referred as I3’UTR) was prompted by results of artificially introducing such RNA species into malignant mammalian cells. Since 1991, we found that the middle part of the 3’UTR of the human nuclear factor for interleukin-6 (NF-IL6) or C/EBP gene exerted tumor suppression effect in vivo. Our subsequent studies showed that transfection of C/EBP 3’UTR led to down-regulation of several genes favorable for malignancy and to up-regulation of some genes favorable for phenotypic reversion. Also, it was shown that the sequences near the termini of the C/EBP 3’UTR were important for its tumor suppression activity. Then, the C/EBP 3’UTR was found to directly inhibit the phosphorylation activity of protein kinase CPKC in SMMC-7721, a hepatocarcinoma cell line. Recently, an AU-rich region in the C/EBP 3’UTR was found also to be responsible for its tumor suppression. Recently we have also found evidence that the independent C/EBP 3’UTR RNA is actually exists in human tissues, such as fetal liver and heart, pregnant uterus, senescent fibroblasts etc. Through 1990’s to 2000’s, world scientists found several 3’UTR RNAs that functioned as artificial independent RNAs in cancer cells and resulted in tumor suppression. Interestingly, majority of genes for these RNAs have promoter-like structures in their 3’UTR regions, although the existence of their transcribed products as independent 3’UTR RNAs is still to be confirmed. Our studies indicate that the independent 3’UTR RNA is a novel non-coding RNA species whose function should be the regulation not of the expression of their original mRNA, but of some essential life activities of the cell as a whole.
    PPT Version | PDF Version
  • Alina Borowska
    Postoperative cognitive dysfunctions after cardiac operations
    PPT Version | PDF Version
  • Ana Domingo Rueda
    Collaborative programme in Pediatric Cardiac Surgery in Ethiopia: Nursery role
    PPT Version | PDF Version
  • Wenru Wang
    Effects of home-based cardiac rehabilitation programme for patients with acute myocardial infarction: A randomized controlled trail
    PPT Version | PDF Version
  • Cicek Senture
    Analyzing The Efficiencies Of Discharge Education For The Patients Who Had A Cardiac Surgery
    PPT Version | PDF Version
  • Katie Kok
    Patient education and anticoagulation therapy in a cardiac population
    PPT Version | PDF Version
  • Adriana Katz
    Na,K-ATPase isoform-selective cardiac glycosides- a potential anti-cancer drug ?
    PPT Version | PDF Version
  • Mauricio Laerte Silva
    Cardiac Diastolic Function in Pediatric AIDS/HIV-carriers: Assessment, Treatment and Prevention of Future Cardiovascular Diseases
    PPT Version | PDF Version
  • Ishfaq A Bukhari
    Protective Effect of Diltiazem and Fenofibrate Against Ischemia-reperfusion Induced Cardiac Arrhythmias in the Isolated Rat Heart.
    PPT Version | PDF Version
  • Hongxin Zhu
    UVRAG and Rubicon Regulate Cardiac Autophagy and Function
    PPT Version | PDF Version
  • Tamer M. A. Mohamed
    Targeting calcium signaling as a novel therapeutic strategy for cardiac hypertrophy and failure
    PDF Version
  • Martin Lehmann
    The Role of Catecholamines in Cardiac Lineage Commitment
    PPT Version | PDF Version
  • M. Rizwan Sohail
    Cardiac Device Infections
    PDF Version

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version